Medlive Technology Co., Ltd. (2192) AI Stock Analysis

• Market Cap: HK$6.36B
• Dividend Yield: 2.72%
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): 19.6
• Beta (1Y): 1.32
• Revenue Growth: 29.81%
• EPS Growth: 10.40%
• Country: HK
• Employees: 747
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.27
• Shares Outstanding: 738,963,750
• 10 Day Avg. Volume: 901,132
• 30 Day Avg. Volume: 1,461,578
• PEG Ratio: 0.72
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 12.28
• P/FCF Ratio: 78.46
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$10.90
• Price Target Upside: 10.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.51
• Revenue Forecast (FY): HK$748.95M

• Rating: 73 Outperform
• Price Target: HK$11.00 ▲(11.90% Upside)
• Action: Downgraded Date: 01/27/26
• Date: Action: Downgraded 01/27/26

The score is driven primarily by strong financial performance (healthy growth, profitability, and a very solid balance sheet). This is offset by a weaker technical picture versus key moving averages and a valuation that appears fair-to-somewhat demanding given the ~25.5 P/E, partially balanced by a ~2.49% dividend yield.

Positive Factors

Revenue Growth

Sustained ~29.8% revenue growth indicates strong demand for Medlive's digital health platforms and expanding market adoption. Over 2–6 months this supports scaling benefits, amortizing fixed costs, and funding incremental R&D and sales investment that reinforce long-term competitive position.

Negative Factors

EBIT Margin Decline

A declining EBIT margin signals persistent cost or operational pressures that may erode profitability even as revenue grows. Over 2–6 months, margin erosion can limit free cash flow expansion and reduce the company's ability to fund R&D or absorb pricing pressure without sacrificing returns.

Medlive Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, ...

Read more

Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, ...

How the Company Makes Money

Medlive Technology generates revenue primarily through the sale of its software solutions and healthcare technology services. The company earns income from licensing its proprietary software to healthcare institutions, which includes installation,...

Read more

Medlive Technology generates revenue primarily through the sale of its software solutions and healthcare technology services. The company earns income from licensing its proprietary software to healthcare institutions, which includes installation,...

Medlive Technology Co., Ltd. Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	627.05M	558.46M	412.00M	314.05M	284.44M	213.53M
Gross Profit	363.84M	327.22M	251.34M	212.74M	200.73M	156.24M
EBITDA	137.14M	121.35M	262.86M	144.56M	76.61M	110.37M
Net Income	323.76M	315.15M	242.30M	117.32M	40.62M	85.20M
Balance Sheet
Total Assets	5.11B	5.11B	4.89B	4.60B	4.12B	227.06M
Cash, Cash Equivalents and Short-Term Investments	3.62B	4.15B	4.40B	4.22B	3.91B	147.09M
Total Debt	14.97M	22.63M	8.19M	11.26M	13.17M	12.07M
Total Liabilities	213.84M	253.56M	248.61M	171.31M	143.37M	75.64M
Stockholders Equity	4.84B	4.80B	4.60B	4.40B	3.95B	151.41M
Cash Flow
Free Cash Flow	133.65M	87.44M	69.34M	69.70M	42.47M	110.42M
Operating Cash Flow	154.64M	108.32M	101.87M	77.19M	44.43M	111.05M
Investing Cash Flow	273.45M	111.02M	-634.95M	-3.59B	-50.54M	13.00K
Financing Cash Flow	-207.96M	-197.89M	-133.13M	-22.38M	3.79B	-2.83M

Medlive Technology Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Neutral. The current price of 9.83 is above the 20-day moving average (MA) of 8.50, above the 50-day MA of 9.44, and below the 200-day MA of 11.83, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 83.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2192.

Medlive Technology Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2192	73 Outperform	HK$6.36B	19.61	6.83%	2.72%	29.81%	10.40%
1099	70 Outperform	HK$65.28B	3.75	8.62%	3.75%	-2.68%	-21.45%
2607	67 Neutral	HK$65.93B	―	7.64%	2.67%	2.77%	39.24%
1931	66 Neutral	HK$1.82B	20.84	4.85%	3.81%	0.33%	-44.28%
2289	60 Neutral	HK$627.48M	7.99	7.98%	8.03%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9955	40 Underperform	HK$463.27M	-0.61	-66.54%	―	-43.86%	-217.25%